Clinical Trial

A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis

Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07532486
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Psoriasis
Enrollment 400 participants
Start Date 2024-07-10
Primary Completion 2027-07-10 (estimated)
Study Completion 2027-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-16